Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price & Analysis
Eupraxia Pharmaceuticals Inc. (EPRX) closed at USD 7.38 on Wednesday, October 28, 2026, up 4.24% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.08; the Oct 28, 2026 session ranged USD 6.9–7.42 on volume of 419,084 shares. Market capitalization is $487.62M, with a 52-week range of USD 5.25–9.32 (NMS). Source: Nexqual, retrieved October 29, 2026 at 06:16 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EPRX.md
Key facts (EPRX)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 16.61 (range 11–25).
- Total return with dividends: 1Y +35.7% vs S&P 500 +13.6%; 5Y +150.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -0.26, revenue estimate $0K.
Analysts (EPRX)
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 16.61 (low 11, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | HC Wainwright & Co. | Reiterated | Buy | $11 |
| 2026-09-24 | Wedbush | Initiated | Outperform | $17 |
Total return (dividends reinvested) (EPRX)
| 1Y (from 2025-10-29) | 5Y (from 2024-04-01) | |
|---|---|---|
| Total return | +35.7% | +150.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +35.8% | +42.8% |
| Volatility (annualized) | 66.4% | 49.7% |
| Max drawdown | -35.9% (Feb 2026→Jul 2026) | -35.4% (Jan 2026→Jul 2026) |
EPRX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.23 | −$0.23 | In line | — |
| — | Quarter ended Dec 31, 2025 | −$0.37 | −$0.16 | Miss −131.3% | — |
| — | Quarter ended Sep 30, 2025 | −$0.19 | −$0.19 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
EPRX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 22, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 22, 2026 |
| Oct 15, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 15, 2026 |
| Oct 9, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 9, 2026 |
| Sep 30, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 30, 2026 |
| Sep 8, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 8, 2026 |
| Aug 13, 2026 | Schedule 13G/A | MANCHESTER MANAGEMENT COMPANY, LLC, MANCHESTER MANAGEMENT PR, LLC: 4.5% of shares, passive 5%+ holder (amended) |
| Aug 13, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 13, 2026 |
| Aug 11, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 11, 2026 |
| Jul 15, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 15, 2026 |
| Jul 13, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 13, 2026 |
| Jul 7, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 7, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
EPRX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.26 | $-0.24 | −$0.01 | $0 | 8 |
| Next quarter (ends Dec 2026) | $-0.27 | $-0.25 | −$0.02 | $0 | 8 |
| Current fiscal year (ends Dec 2026) | $-0.98 | $-0.97 | −$0.01 | $0 | 8 |
| Next fiscal year (ends Dec 2027) | $-1.04 | $-0.90 | −$0.14 | $709,820 | 10 |
Key Statistics (as of October 29, 2026 at 06:16 UTC)
| Price | USD 7.38 |
|---|---|
| Change | ▲ 4.24% (up) |
| Previous Close | USD 7.08 |
| Open | USD 7.08 |
| Day Range | USD 6.9 – 7.42 |
| 52-Week Range | USD 5.25 – 9.32 |
| Volume | 419,084 shares |
| Market Cap | $487.62M |
| Exchange | NMS |
Technical Analysis (EPRX)
Nexqual's technical model rates EPRX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 06:16 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.5 (neutral) |
| vs SMA50 | Below (USD 7.59) |
| MACD | -0.15 (negative) |
Analyst Ratings (EPRX)
Wall Street analysts rate EPRX "Buy" based on 12 analysts, with a mean price target of USD 16.61 (range USD 11–25), per Nexqual as of October 29, 2026 at 06:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 16.61 |
| High Target | USD 25 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (EPRX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.23 vs est -0.23 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -0.16 ▼ miss |
| 2025-09-30 | USD -0.19 vs est -0.19 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:16 UTC.
Financials & Fundamentals (EPRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -66.70% |
| Debt / Equity | 0.01 |
| Current Ratio | 16 |
| Total Cash | $133.66M |
| Total Debt | $1.84M |
Source: Nexqual, October 29, 2026 at 06:16 UTC.
Financial Health Score (EPRX)
Nexqual rates Eupraxia Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $134M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$37M (TTM) |
| Efficiency | Critical — ROE -67%, ROA -43.7% |
Ownership (EPRX)
| Insider Ownership | +12.11% |
|---|---|
| Institutional Ownership | +43.34% |
| Shares Outstanding | 66.07M |
| Float | 55.67M |
Source: Nexqual, October 29, 2026 at 06:16 UTC.
Leadership (EPRX)
Eupraxia Pharmaceuticals Inc. is led by James A. Helliwell FRCPC, CEO & Director, per Nexqual as of October 29, 2026 at 06:16 UTC.
| CEO & Director | James A. Helliwell FRCPC |
|---|---|
| Chief Financial Officer | Alexander John Rothwell Eng. |
| Executive Vice President Corporate Services & People | Wajida Leclerc B.A., CCP, CHRP |
| Executive Vice President of Technical Operations | Jeffrey Millard |
Major Backers & Investors (EPRX)
Notable institutional backers of Eupraxia Pharmaceuticals Inc. include Beutel, Goodman & Company Ltd, Affinity Asset Advisors, Llc, Balyasny Asset Management LP, according to Nexqual as of October 29, 2026 at 06:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Beutel, Goodman & Company Ltd | 5.58% |
| Affinity Asset Advisors, Llc | 2.54% |
| Balyasny Asset Management LP | 2.08% |
| Vivo Capital, LLC | 2.08% |
| Scotia Capital Inc. | 2.07% |
| Pfm Health Sciences, Lp | 1.86% |
| Great Point Partners LLC | 1.85% |
| Jupiter Topco LLC | 1.61% |
Source: Nexqual, October 29, 2026 at 06:16 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:16 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt